Hypereosinophilic syndrome: Current approach to diagnosis and treatment

Annual Review of Medicine

Volumn 60, Issue , 2009, Pages 293-306

  Klion, Amy ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Chronic eosinophilic leukemia; Chronic eosinophilic pneumonia; Churg Strauss vasculitis; Eosinophil associated gastrointestinal disorders; Episodic angioedema and eosinophilia; Familial eosinophilia

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN; HYDROXYUREA; IMATINIB; IMMUNOGLOBULIN; MEDI 563; MEPOLIZUMAB; MONOCLONAL ANTIBODY; NILOTINIB; PEGINTERFERON; PLACEBO; PREDNISONE; RECOMBINANT ALPHA INTERFERON; RESLIZUMAB; SORAFENIB; UNCLASSIFIED DRUG;

ANGIONEUROTIC EDEMA; ASTHMA; BONE MARROW TRANSPLANTATION; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOPENIA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; EOSINOPHILIA; EOSINOPHILIC ESOPHAGITIS; EOSINOPHILIC LEUKEMIA; FAMILIAL EOSINOPHILIA; HUMAN; HYPEREOSINOPHILIC SYNDROME; LOEFFLER PNEUMONIA; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MONOCYTIC LEUKEMIA; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPEREOSINOPHILIC SYNDROME;

EID: 67650741780     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.60.062107.090340     Document Type: Review

References (66)

1. Weller PF, Bubley GJ. 1994. The idiopathic hypereosinophilic syndrome. Blood 83:2759-79
2. Cools J, DeAngelo DJ, Gotlib J, et al. 2003. A novel tyrosine kinase created by the fusion of the PDGFRA and FIP1L1 genes is a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348:1201-14
3. Rioux JD, Stone VA, Daly MJ, et al. 1998. Familial eosinophilia maps to the cytokine gene cluster on human chromosomal region 5q31-q33. Am. J. Hum. Genet. 63:1086-94
4. Roufosse F, Schandene L, Sibille C, et al. 2000. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br. J. Haematol. 109:540-48
5. Klion AD, Law MA, Riemenschneider W, et al. 2004. Familial eosinophilia: a benign disorder? Blood 103:4040-55
6. Klion AD, Noel P, Akin C, et al. 2003. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis and imatinib-responsiveness. Blood 101:4660-66
7. Chusid MJ, David DC,West BC, et al. 1975. The hypereosinophilic syndrome. Analysis of fourteen cases with review of the literature. Medicine 54:1-27
8. Simon HU, Plotz SG, Dummer R, et al. 1999. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N. Engl. J. Med. 341:1112-20
9. Morgan SJ, Prince HM, Westerman DA, et al. 2003. Clonal T-helper lymphocytes and elevated IL-5 levels in episodic angioedema and eosinophilia (Gleich's syndrome). Leuk. Lymph. 44:1623-25
10. Klion AD, Bochner BS, Gleich GJ, et al. 2006. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J. Allergy Clin. Immunol. 117:1292-302
11. Nutman TB, Miller KD, Mulligan M, et al. 1986. Loa loa infection in temporary residents of endemic regions: recognition of a hyperresponsive syndrome with characteristic clinical manifestations. J. Infect. Dis. 154:10-18
12. Solomon J, Schwarz M. 2006. Drug-, toxin-, and radiation therapy-induced eosinophilic pneumonia. Semin. Respir. Crit. Care Med. 27:192-97
13. Hoppes T, Prikis M, Segal A. 2007. Four cases of nafcillin-associated acute interstitial nepritis in one institution. Nat. Clin. Pract. Nephrol. 3:456-61
14. Hertzman PA, Blevins WL, Mayer J, et al. 1990. Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. N. Engl. J. Med. 322:869-73
15. Peyriere H, Dereure O, Breton H, et al. 2006. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: Does a DRESS syndrome really exist? Br. J. Dermatol. 155:422-28
16. Tas S, Simonart T. 2003. Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update. Dermatology 206:353-56
17. Roberts LJ, Huffam SE, Walton SF, et al. 2005. Crusted scabies: clinical and immunologic findings in seventy-eight patients and a review of the literature. J. Infect. Dis. 50:375-81
18. Starr J, Pruett JH, Yunginger JW, et al. 2000. Myiasis due to Hypoderma lineatum infection mimicking the hypereosinophilic syndrome. Mayo Clin. Proc. 75:755-59
19. Renston JP, Goldman ES, Hsu RM, et al. 2000. Peripheral blood eosinophilia in association with sarcoidosis. Mayo Clin. Proc. 75:586-90
20. Wright R, Truelove SC. 1966. Circulating and tissue eosinophils in ulcerative colitis. Am. J. Dig. Dis. 11:831-46
21. Cohen AJ, Steigbigel RT. 1996. Eosinophilia in patients infected with human immunodeficiency virus. J. Infect. Dis. 174:615-18
22. Murata K, Yamada Y, Kamihira S, et al. 1992. Frequency of eosinophilia in adult T cell leukemia/lymphoma. Cancer 69:966-71
23. Kim YJ, Dale JK, Noel P, et al. 2007. Eosinophilia is associated with a higher mortality rate among patients with autoimmune lymphoproliferative syndrome. Am. J. Hematol. 82:615-24
24. Utsonomiya A, Ishida T, Inagaki A, et al. 2007. Clinical significance of a blood eosinophilia in adult T-cell leukemia/lymphoma: a blood eosinophilia is a significant unfavorable prognostic factor. Leuk. Res. 31:915-20
25. Griffin JH, Leung J, Bruner R, et al. 2003. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc. Natl. Acad. Sci. USA 100:7830-35
26. Gleich GJ, Schroeter AL, Marcoux JP, et al. 1984. Episodic angioedema associated with eosinophilia. N. Engl. J. Med. 310:1621-26
27. Blanchard C, Wang N, Stringer KF, et al. 2006. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J. Clin. Invest. 115:536-47
28. Pardanani A, Brockman SR, Paternoster SF, et al. 2004. FIP1L1/PDGFRA fusion: prevalence and clinicopathologic correlates in 89 patients with moderate to severe eosinophilia. Blood 104:3038-45
29. Roche-Lestienne C, Lepers S, Soenen-Cornu V, et al. 2005. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia 19:792-98
30. Curtis CE, Grand FH, Musto P, et al. 2007. Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukemia. Br. J. Haematol. 138:77-81
31. Pardanani A, Ketterling RP, Li CY, et al. 2006. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk. Res. 30:965-70
32. Bain BJ, Fletcher SH. 2007. Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol. Allergy Clin. North Am. 27:377-88
33. Tefferi A, Vardiman JW. 2008. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22:14-22
34. Maric I, Robyn J, Metcalfe DD,et al. 2007.KITD816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J. Allergy Clin. Immunol. 120:680-87
35. Cogan E, Schandene L, Crusiaux A, et al. 1994. Brief report: clonal proliferation of type 2 helper cells in a man with the hypereosinophilic syndrome. N. Engl. J. Med. 330:535-38
36. Roufosse F, Cogan E, Goldman M. 2007. Lymphocytic variant hypereosinophilic syndromes. Immunol. Allergy Clin. North Am. 27:389-413
37. de Lavareille A, Roufosse F, Schmid-Grendelmeier P, et al. 2002. High serum thymus and activationregulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome. J. Allergy Clin. Immunol. 110:476-79
38. Rothenberg ME, Klion AD, Roufosse FE, et al. 2008. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N. Engl. J. Med. 358:1215-28
39. + T-cell clones associated with the lymphocytic variant of hypereosinophilic syndrome. Haematologica 90:753-65
40. Vaklavas C, Tefferi A, Butterfield J, et al. 2007. 'Idiopathic' eosinophilia with an occult T-cell clone: prevalence and clinical course. Leuk. Res. 31:691-94
41. Manganelli P, Giacosa R, Fietta P, et al. 2003. Familial vasculitides: Churg-Strauss syndrome and Wegener's granulomatosis in 2 first-degree relatives. J. Rheumatol. 30:618-21
42. Collins MH, Blanchard C, Abonia JP, et al. 2008. Clinical, pathologic, and molecular characterization of familial esophagitis compared to sporadic cases. Clin. Gastroenterol. Hepatol. 6:621-29
43. Lin AY, Nutman TB, Kaslow D, et al. 1998. Familial eosinophilia: clinical and laboratory results of a U.S. kindred. Am. J. Med. Gen. 76:229-37
44. Butterfield J. 2007. Therapy of hypereosinophilic syndromes with prednisone, hydroxyurea and interferon. Immunol. Allergy Clin. North Am. 27:493-518
45. Pitini V, Arrigo C, Azzarello D, et al. 2003. Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood 102:3456-57
46. Parrillo JE, Fauci AS, Wolff SM. 1978. Therapy of the hypereosinophilic syndrome. Ann. Intern. Med. 89:167-72
47. Coutant G, Bletry O, Prin L, et al. 1993. Treatment of hypereosinophilic syndromes of myeloproliferative expression with the combination of hydroxyurea and interferon alpha. Apropos of 7 cases. Ann. Med. Interne. 144:243-50
48. Butterfield JH, Sharkey SW. 2006. Control of hypereosinophilic syndrome-associated recalcitrant coronary artery spasm by combined treatment prednisone, imatinib mesylate and hydroxyurea. Exp. Clin. Cardiol. 11:25-28
49. Schandene L, Roufosse F, de Lavareille A, et al. 2000. Interferon alpha prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosinophilia. Blood 96:4285-92
50. Klion AD, Robyn J, Akin C, et al. 2003. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 103:473-78
51. Simon D, Salemi S, Yousefi S, et al. 2008. Primary resistance to imatinib in Fip1 like 1 platelet-derived growth factor receptor alpha-positive eosinophilic leukemia. J. Allergy Clin. Immunol. 121:1054-56
52. Klion AD, Robyn J, Maric I, et al. 2007. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood 110:3552-56
53. Rotoli B, Catalano L, Galderisi M, et al. 2004. Rapid reversion of Loeffler's endocarditis by imatinib in early stage clonal hypereosinophilic syndrome. Leuk. Lymph. 45:2503-7
54. Helbig G, Stella-Holowiecka B, Majewski M, et al. 2008. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukemia in FIP1L1/PDGFRA-expressing patients. Br. J. Haematol. 141:200-4
55. Baccarani M, Cilloni D, Rondoni M, et al. 2007. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRA alpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 92:1173-79
56. Verstovsek S, Giles FJ, Quintas-Cardama A, et al. 2006. Activity of AMN 107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFRA-alpha-expressing cells. Leuk. Res. 30:1499-505
57. Lierman E, Folens C, Stover EH, et al. 2006. Sorafenib is a potent inhibitor of FIP1L1-PDGFRAalpha and the imatinib-resistant FIP1L1-PDGFRAalpha T6741 mutant. Blood 108:1374-76
58. Leckie MJ, ten Brinke A, Khan J, et al. 2000. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356:2144-48
59. Flood-Page P, Swenson C, Faiferman I, et al. 2007. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am. J. Respir. Crit. Care Med. 176:1062-71
60. Kips JC, O'Connor BJ, Langley SJ, et al. 2003. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am. J. Respir. Crit. Care Med. 167:1655-69
61. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. 2003. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respir. Crit. Care Med. 167:199-204
62. Garrett JK, Jameson SC, Thomson B, et al. 2003. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J. Allergy Clin. Immunol. 113:115-19
63. Klion AD, Law MA,Noel P, et al. 2004. Safety and efficacy of the monoclonal anti-interleukin 5 antibody, SCH55700, in the treatment of patients with the hypereosinophilic syndrome. Blood 103:2939-41
64. Kim YJ, Prussin C, Martin B, et al. 2004. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL5 antibody SCH55700. J. Allergy Clin. Immunol. 114:1449-55
65. Stein ML, Collins MH, Villanueva JM, et al. 2006. Anti-IL-5 (meplizumab) therapy for eosinophilic esophagitis. J. Allergy Clin. Immunol. 118:1312-19
66. Pitini V, Teti D, Arrigo C, et al. 2004. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report. Br. J. Haematol. 127:477